Increased EZH-2 activity can be found in up to 85% of epithelial ovarian cancer cases, yet its biological impact is influenced by the interplay of EZH-2 and other epigenetic regulators such as the components of the BAF complex [32,33]. This evidence concerns the gene BANF1 and ovarian carcinoma.